Answers are grounded in this paper and cite their sources.
Several agents are approved by the US Food and Drug Administration for pediatric psoriasis, and dupilumab is approved for pediatric atopic dermatitis (AD). Herein, the authors discuss the latest developments in the treatment landscape for pediatric psoriasis and AD.
No takes yet. Share an insight, caveat, or question.
Scott et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: